Nervous System News and Research

Latest Nervous System News and Research

Positive top line results from Shire's LDX phase III study on ADHD

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.

22 Oct 2011

Romark announces results from NT-300 Phase 2B-3 trial on influenza

Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.

22 Oct 2011

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech, a member of the Roche Group, today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease.

21 Oct 2011

Preclinical data from Teva's COPAXONE study on multiple sclerosis

Teva Pharmaceutical Industries Ltd. today announced preclinical data demonstrating reparative and neuroprotective effects of treatment with COPAXONE (glatiramer acetate injection) in experimental autoimmune encephalomyelitis (EAE) models.

21 Oct 2011

Tamandare Explorations is now Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".

20 Oct 2011

OPHN1 protein mediates mGluR-dependent longterm depression at synapses

Scientists at Cold Spring Harbor Laboratory (CSHL) have solved part of a puzzle concerning the relationship between changes in the strength of synapses - the tiny gaps across which nerve cells in the brain communicate - and dysfunctions in neural circuits that have been linked with drug addiction, mental retardation and other cognitive disorders.

20 Oct 2011

JHU, Eisai enter drug-discovery research collaboration for brain disorders

The Johns Hopkins University (JHU) has entered into a drug-discovery research collaboration with Eisai, a pharmaceutical company based in Tokyo, to develop proprietary small-molecule drugs for a range of brain conditions such as schizophrenia, pain, brain tumors and Alzheimer's disease.

20 Oct 2011

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011

Oral laquinimod shows promise against multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability progression and brain volume loss.

19 Oct 2011

FSU biologists devise new way to watch how cells move

For better and for worse, human health depends on a cell's motility -- the ability to crawl from place to place. In every human body, millions of cells -are crawling around doing mostly good deeds --- though if any of those crawlers are cancerous, watch out.

19 Oct 2011

Sam Houston State receives NIJ/FSF grant to investigate BKA designer drugs

In October 2011 the National Institute of Justice (NIJ) and the Forensic Science Foundation (FSF) funded a capstone project proposal in the Master of Forensic Science Program at Sam Houston State University to investigate the designer drugs known as "Bath Salts."

19 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

UTA technology could reduce time and cost to finding a cure for Alzheimer's

Technology developed by researchers at The University of Texas at Austin could significantly reduce the time and cost to finding a cure for Alzheimer's disease and help answer one of the greatest biological questions: why do we age?

18 Oct 2011

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration has approved its Investigational New Drug application for the Phase I/IIa clinical development of UshStat, a novel gene-based treatment for Usher syndrome type 1B.

18 Oct 2011

Circadian disruption and sleep restriction increase risk of MS in teens

Researchers from Sweden have uncovered an association between shift work and increased risk of multiple sclerosis. Those who engage in off-hour employment before the age of 20 may be at risk for MS due to a disruption in their circadian rhythm and sleep pattern. Findings of this novel study appear today in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association and Child Neurology Society.

18 Oct 2011

LRI launches major lupus research initiative

The Lupus Research Institute (LRI) launched a major international initiative aimed at attracting the highest level scientists to conduct pioneering research to discover the fundamental root causes of lupus, explore the potential for a cure, and transform the field of lupus research.

18 Oct 2011

Micro-electrical stimulators for spinal cord injuries

A new wireless device to help victims of spinal cord injury is receiving attention in the research community. Mesut Sahin, PhD, associate professor, in the department of biomedical engineering at NJIT, recently has published and presented news of his findings to develop micro-electrical stimulators for individuals with spinal cord injuries.

18 Oct 2011

Reversing low VEGF levels may potentially treat patients with SCA1

A groundbreaking study in the journal Nature Medicine suggests what could become the first effective treatment for a debilitating and fatal disease of the central nervous system called SCA1.

18 Oct 2011

Link between auditory working memory, musical aptitude and reading ability

Auditory working memory and attention, for example the ability to hear and then remember instructions while completing a task, are a necessary part of musical ability. But musical ability is also related to verbal memory and literacy in childhood. New research published in BioMed Central's open access journal Behavioral and Brain Functions shows how auditory working memory and musical aptitude are intrinsically related to reading ability, and provides a biological basis for this link.

18 Oct 2011

Heart-related treatments may improve wellbeing of patients with COPD

A new study has found that processes that control heart rate play an important role in the quality of life experienced by patients with chronic obstructive pulmonary disease.

15 Oct 2011